© Reuters.
By Davit Kirakosyan
Investing.com — Here is your Pro Recap of the most head-turning deal dispatches you may have missed this week: disappointment at SiriusPoint, positive news for Microsoft-Activision, Shockwave Medical attracts two suitors; and Syneos Health gets bought out.
InvestingPro subscribers got this news in rapid fire. Never be left in the dust again.
Dan Loeb is no longer exploring acquisition of SiriusPoint
Siriuspoint (NYSE:) shares dropped more than 9% on Friday after Daniel Loeb declared it is no longer exploring a potential acquisition of the company, as reported in real time on InvestingPro.
This comes after a month the billionaire investor, who manages Third Point hedge fund, expressed his interest in taking SiriusPoint private. According to the regulatory filing, Loeb and the insurance firm failed to agree on the value of the deal.
EU set to approve Microsoft-Activision deal next week
EU is poised to approve Microsoft (NASDAQ:) – Activision Blizzard (NASDAQ:) deal next week, according to a report from Bloomberg on Wednesday.
This comes after the United Kingdom’s Competition and Markets Authority (CMA) issued an order last month blocking the pending deal, citing concerns that the deal would harm competition in the fast-growing cloud gaming market.
Shockwave Medical attracts more takeover interest
Shockwave Medical (NASDAQ:) picked up takeover interest from two additional suitors, Johnson & Johnson (NYSE:) and Medtronic (NYSE:), according to InvestingPro sources.
Earlier this week, it was reported that discussions between the company and the original suitor Boston Scientific (NYSE:) have ended due to a disagreement on the price.
During the company’s earnings call this week, Shockwave CEO Douglas Godshall mentioned that although they do not address rumors and speculation, they would carefully consider any offer that is presented to their Board.
Syneos Health bought out for $7B
Syneos Health (NASDAQ:) shares jumped more than 8% on Wednesday following the official announcement of its acquisition by a private consortium of investment firms for $43 per share, in an all-cash deal valuing the company at around $7.1 billion.
The consortium includes Elliott Investment Management, Patient Square Capital, and Veritas Capital.
Get a leg up on the market: Always be the first to know with InvestingPro.
Start your free 7-day trial now.
Read the full article here
